US2003018180A1PendingUtilityA1
Secreted protein HFEAF41
Est. expiryMar 21, 2017(expired)· nominal 20-yr term from priority
Inventors:Paul YoungJohn GreeneAnn FerrieSteven RubenCraig RosenRoxanne DuanJing-Shan HuKimberly FlorenceHenrik OlsenReinhard EbnerLauie BrewerPaul A. MooreYanggu ShiDavid LafleurJian Ni
A61P 35/02A61P 7/02A61P 37/04A61P 7/06A61P 3/10A61P 9/10A61P 37/08A61P 37/06A61P 35/00A61P 9/12A61P 25/20A61P 25/16A61P 27/02A61P 25/18A61P 25/30A61P 3/02A61P 29/00A61P 25/00A61P 25/28A61P 3/04A61P 17/06A61P 11/06A61K 38/00A61P 17/02C07K 14/47A61P 15/08A61P 17/00A61P 21/04G01N 33/6893A61P 15/16A61P 19/10C12Q 1/6883A61P 13/12A61P 19/02
54
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to 87 novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating disorders related to these novel human secreted proteins.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated protein comprising amino acid residues 29 to 99 of SEQ ID NO:142.
2 . The isolated protein of claim 1 which comprises amino acid residues 2 to 99 of SEQ ID NO:142.
3 . The isolated protein of claim 1 which comprises amino acid residues 1 to 99 of SEQ ID NO:142.
4 . The protein of claim 1 which comprises a heterologous polypeptide sequence.
5 . A composition comprising the protein of claim 1 and a pharmaceutically acceptable carrier.
6 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 1 by a cell: and (b) recovering said protein.
7 . An isolated protein comprising the amino acid sequence of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
8 . An isolated protein of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923, excepting the N-terminal methionine.
9 . An isolated protein of claim 7 which comprises the amino acid sequence of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
10 . The protein of claim 7 which comprises a heterologous polypeptide sequence.
11 . A composition comprising the protein of claim 7 and a pharmaceutically acceptable carrier.
12 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 7 by a cell; and (b) recovering said protein.
13 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 29 to 99 of SEQ ID NO:142.
14 . The isolated protein of claim 13 wherein said polypeptide sequence is at least 95% identical to amino acid residues 29 to 99 of SEQ ID NO:142.
15 . The protein of claim 13 which comprises a heterologous polypeptide sequence.
16 . A composition comprising the protein of claim 13 and a pharmaceutically acceptable carrier.
17 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 13 by a cell; and (b) recovering said protein.
18 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to amino acid residues 1 to 99 of SEQ ID NO:142.
19 . The isolated protein of claim 18 wherein said polypeptide sequence is at least 95% identical to amino acid residues 1 to 99 of SEQ ID NO:142.
20 . The protein of claim 18 which comprises a heterologous polypeptide sequence.
21 . A composition comprising the protein of claim 18 and a pharmaceutically acceptable carrier.
22 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 18 by a cell; and (b) recovering said protein.
23 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
24 . The isolated protein of claim 23 wherein said polypeptide sequence is at least 95% identical to the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
25 . The protein of claim 23 which comprises a heterologous polypeptide sequence.
26 . A composition comprising the protein of claim 23 and a pharmaceutically acceptable carrier.
27 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 23 by a cell; and (b) recovering said protein.
28 . An isolated protein comprising a polypeptide sequence which is at least 90% identical to the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
29 . The isolated protein of claim 28 wherein said polypeptide sequence is at least 95% identical to the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
30 . The protein of claim 28 which comprises a heterologous polypeptide sequence.
31 . A composition comprising the protein of claim 28 and a pharmaceutically acceptable carrier.
32 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 28 by a cell; and (b) recovering said protein.
33 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 29 to 99 of SEQ ID NO:142.
34 . The isolated protein of claim 33 which comprises at least 50 contiguous amino acid residues of amino acid residues 29 to 99 of SEQ ID NO:142.
35 . The protein of claim 33 which comprises a heterologous polypeptide sequence.
36 . A composition comprising the protein of claim 33 and a pharmaceutically acceptable carrier.
37 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 33 by a cell; and (b) recovering said protein.
38 . An isolated protein comprising at least 30 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
39 . The isolated protein of claim 38 which comprises at least 50 contiguous amino acid residues of the secreted portion of the polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
40 . The protein of claim 38 which comprises a heterologous polypeptide sequence.
41 . A composition comprising the protein of claim 38 and a pharmaceutically acceptable carrier.
42 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 38 by a cell; and (b) recovering said protein.
43 . An isolated protein comprising at least 30 contiguous amino acid residues of amino acid residues 1 to 99 of SEQ ID NO:142.
44 . The isolated protein of claim 43 which comprises at least 50 contiguous amino acid residues of amino acid residues 1 to 99 of SEQ ID NO:142.
45 . The protein of claim 43 which comprises a heterologous polypeptide sequence.
46 . A composition comprising the protein of claim 43 and a pharmaceutically acceptable carrier.
47 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 43 by a cell; and (b) recovering said protein.
48 . An isolated protein comprising at least 30 contiguous amino acid residues of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
49 . The isolated protein of claim 48 which comprises at least 50 contiguous amino acid residues of the complete polypeptide encoded by the HFEAF41 cDNA contained in ATCC Deposit No. 97923.
50 . The protein of claim 48 which comprises a heterologous polypeptide sequence.
51 . A composition comprising the protein of claim 48 and a pharmaceutically acceptable carrier.
52 . An isolated protein produced by the method comprising:
(a) expressing the protein of claim 48 by a cell; and (b) recovering said protein.Join the waitlist — get patent alerts
Track US2003018180A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.